Literature DB >> 11251277

Trimodality management of malignant pleural mesothelioma.

G Maggi1, C Casadio, R Cianci, O Rena, E Ruffini.   

Abstract

OBJECTIVE: We reviewed our experience with trimodality management of malignant pleural mesothelioma (MPM).
METHODS: From September 1998 to August 2000, 32 consecutive patients with histological diagnosis of MPM underwent trimodality therapy, including surgery followed by adjuvant chemotherapy and radiation therapy. Surgery consisted of pleurectomy/decortication (P/D) or pleural-pericardial-pneumonectomy and diaphragm (PPPD). Pre-operative staging according to the Brigham Staging System was accomplished using computed tomography (CT) and magnetic resonance imaging (MRI); patients with evident extrapleural spread were excluded.
RESULTS: Our series included 21 men and 11 women with a median age of 53.5 years (range 40-69). Histologically, there were 26 epithelial, four mixed and two sarcomatous MPM. Post-surgical staging was as follows: six patients were at Stage I; of these, two received a P/D and four a PPPD. Ten patients were at Stage II and all received a PPPD; 16 patients were at Stage III (under-staged pre-operatively): of these, nine patients presented extrapleural lymph node metastases (N2) and all received a PPPD, seven patients presented with chest wall or mediastinal invasion (T4) with macroscopic residual tumour, and all received a de-bulking P/D. We observed major complications in ten patients: six bleeding, two respiratory insufficiency and two nerve paralysis. There were two perioperative deaths (6.25% mortality). Twenty-seven patients out of 30 surviving surgery had a follow-up greater than 6 months; 21 patients out of 27 are alive with a median follow-up of 12.5 months.
CONCLUSIONS: (1) Trimodality therapy is feasible in selected patients with MPM and has an acceptable operative mortality rate. (2) Our current pre-operative staging based on CT/MRI looks rather inaccurate and needs to be improved. (3) The high rate of post-surgical N2 patients or with diffusion to the inferior surface of the diaphragm may suggest the use of routine mediastinoscopy and laparoscopy for a more appropriate patient selection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11251277     DOI: 10.1016/s1010-7940(01)00594-2

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  12 in total

1.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

2.  Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery.

Authors:  Marjorie G Zauderer; Lee M Krug
Journal:  Ann Cardiothorac Surg       Date:  2012-11

3.  Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma.

Authors:  Kenichi Okubo; Makoto Sonobe; Takuji Fujinaga; Tsuyoshi Shoji; Hiroaki Sakai; Ryo Miyahara; Toru Bando; Hiroshi Date; Keiko Shibuya; Masahiro Hiraoka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-11-12

4.  Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy.

Authors:  Hironori Ishibashi; Masashi Kobayashi; Chihiro Takasaki; Kenichi Okubo
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-03-07

Review 5.  Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.

Authors:  Andrew R Haas; Daniel H Sterman
Journal:  Clin Chest Med       Date:  2013-01-17       Impact factor: 2.878

6.  The evolution of multimodality therapy for malignant pleural mesothelioma.

Authors:  Marjorie G Zauderer; Lee M Krug
Journal:  Curr Treat Options Oncol       Date:  2011-06

7.  Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma.

Authors:  Rong Liu; Aaron H Colby; Denis Gilmore; Morgan Schulz; Jialiu Zeng; Robert F Padera; Orian Shirihai; Mark W Grinstaff; Yolonda L Colson
Journal:  Biomaterials       Date:  2016-06-23       Impact factor: 12.479

Review 8.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 9.  Radiotherapy for malignant pleural mesothelioma.

Authors:  E Chapman; E G Berenstein; M Diéguez; Z Ortiz
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

Review 10.  Photodynamic therapy for mesothelioma.

Authors:  S M Hahn; R P Smith; J Friedberg
Journal:  Curr Treat Options Oncol       Date:  2001-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.